{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Ipatasertib&page=2", "query": { "intervention": "Ipatasertib", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Ipatasertib&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-26T02:21:09.321Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04486352", "title": "A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Endometrial Cancer" ], "interventions": [ { "name": "Atezolizumab - 28 Day Cycle", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Ipatasertib", "type": "DRUG" }, { "name": "Talazoparib", "type": "DRUG" }, { "name": "Trastuzumab emtansine", "type": "DRUG" }, { "name": "Tiragolumab", "type": "DRUG" }, { "name": "Atezolizumab - 21 Day Cycle", "type": "DRUG" }, { "name": "Inavolisib", "type": "DRUG" }, { "name": "Letrozole", "type": "DRUG" }, { "name": "Giredestrant", "type": "DRUG" }, { "name": "Abemaciclib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Alliance Foundation Trials, LLC.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 148, "start_date": "2021-10-20", "completion_date": "2027-10", "has_results": false, "last_update_posted_date": "2026-04-01", "last_synced_at": "2026-09-26T02:21:09.321Z", "location_count": 21, "location_summary": "Duarte, California • San Francisco, California • Washington D.C., District of Columbia + 18 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Miami Beach", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT04486352" }, { "nct_id": "NCT04467801", "title": "Ipatasertib and Docetaxel in Metastatic NSCLC Patients Who Have Failed 1st Line Immunotherapy", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "NSCLC Stage IV", "NSCLC Stage IIIB" ], "interventions": [ { "name": "Ipatasertib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Jun Zhang, MD, PhD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2021-09-14", "completion_date": "2025-08", "has_results": false, "last_update_posted_date": "2023-11-07", "last_synced_at": "2026-09-26T02:21:09.321Z", "location_count": 5, "location_summary": "Fairway, Kansas • Kansas City, Kansas • Overland Park, Kansas + 2 more", "locations": [ { "city": "Fairway", "state": "Kansas" }, { "city": "Kansas City", "state": "Kansas" }, { "city": "Overland Park", "state": "Kansas" }, { "city": "Kansas City", "state": "Missouri" }, { "city": "Lee's Summit", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT04467801" }, { "nct_id": "NCT04931342", "title": "A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ovarian Cancer" ], "interventions": [ { "name": "Ipatasertib", "type": "DRUG" }, { "name": "Cobimetinib", "type": "DRUG" }, { "name": "Trastuzumab Emtansine", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Giredestrant", "type": "DRUG" }, { "name": "Abemaciclib", "type": "DRUG" }, { "name": "Inavolisib", "type": "DRUG" }, { "name": "Palbociclib", "type": "DRUG" }, { "name": "Letrozole", "type": "DRUG" }, { "name": "Olaparib", "type": "DRUG" }, { "name": "Luteinizing Hormone-Releasing Hormone (LHRH) Agonists", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 176, "start_date": "2021-10-07", "completion_date": "2028-05-30", "has_results": false, "last_update_posted_date": "2026-09-10", "last_synced_at": "2026-09-26T02:21:09.321Z", "location_count": 8, "location_summary": "San Francisco, California • St Louis, Missouri • Charlotte, North Carolina + 5 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Charlotte", "state": "North Carolina" }, { "city": "Columbus", "state": "Ohio" }, { "city": "Oklahoma City", "state": "Oklahoma" } ], "official_url": "https://clinicaltrials.gov/study/NCT04931342" }, { "nct_id": "NCT03959891", "title": "AKT Inhibitor, Ipatasertib, With Endocrine and CDK 4/6 Inhibitor for Patients With Metastatic Breast Cancer (TAKTIC)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Ipatasertib", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Aromatase Inhibitor", "type": "DRUG" }, { "name": "Palbociclib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 77, "start_date": "2019-05-30", "completion_date": "2027-08", "has_results": false, "last_update_posted_date": "2026-08-19", "last_synced_at": "2026-09-26T02:21:09.321Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03959891" }, { "nct_id": "NCT02536391", "title": "Ipatasertib (GDC-0068) Study to Evaluate Formulation Change and Food Effect on Bioavailability in Healthy Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "Ipatasertib (capsule)", "type": "DRUG" }, { "name": "Ipatasertib (tablet)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 18, "start_date": "2015-10", "completion_date": "2015-11", "has_results": false, "last_update_posted_date": "2016-11-02", "last_synced_at": "2026-09-26T02:21:09.321Z", "location_count": 1, "location_summary": "Madison, Wisconsin", "locations": [ { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT02536391" }, { "nct_id": "NCT01362374", "title": "Safety and Clinical Pharmacology of GDC-0068 in Combination With Docetaxel, Fluoropyrimidine Plus Oxaliplatin, Paclitaxel, or Enzalutamide in Participants With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasms" ], "interventions": [ { "name": "5-FU", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Enzalutamide", "type": "DRUG" }, { "name": "Ipatasertib", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 122, "start_date": "2011-07-11", "completion_date": "2020-10-16", "has_results": false, "last_update_posted_date": "2022-01-12", "last_synced_at": "2026-09-26T02:21:09.321Z", "location_count": 7, "location_summary": "San Francisco, California • Sarasota, Florida • Boston, Massachusetts + 4 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Las Vegas", "state": "Nevada" } ], "official_url": "https://clinicaltrials.gov/study/NCT01362374" }, { "nct_id": "NCT03800836", "title": "A Study to Evaluate the Safety and Efficacy of Ipatasertib in Combination With Atezolizumab and Paclitaxel or Nab-Paclitaxel in Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Ipatasertib", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Nab-Paclitaxel", "type": "DRUG" }, { "name": "AC", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 139, "start_date": "2018-02-13", "completion_date": "2022-03-16", "has_results": true, "last_update_posted_date": "2024-10-30", "last_synced_at": "2026-09-26T02:21:09.321Z", "location_count": 1, "location_summary": "Long Beach, California", "locations": [ { "city": "Long Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03800836" }, { "nct_id": "NCT04177108", "title": "A Study of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Triple-Negative Breast Cancer" ], "interventions": [ { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Ipatasertib", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Placebo for Atezolizumab", "type": "DRUG" }, { "name": "Placebo for Ipatasertib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 242, "start_date": "2019-11-25", "completion_date": "2023-02-28", "has_results": true, "last_update_posted_date": "2024-03-27", "last_synced_at": "2026-09-26T02:21:09.321Z", "location_count": 31, "location_summary": "Mobile, Alabama • Springdale, Arkansas • Los Angeles, California + 25 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Springdale", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04177108" }, { "nct_id": "NCT03840200", "title": "A Study Evaluating the Safety, Pharmacokinetics and Efficacy of Ipatasertib Administered in Combination With Rucaparib in Participants With Advanced Breast, Ovarian Cancer, and Prostate Cancer.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer", "Prostate Cancer", "Ovarian Cancer" ], "interventions": [ { "name": "Ipatasertib", "type": "DRUG" }, { "name": "Rucaparib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 51, "start_date": "2019-06-12", "completion_date": "2022-01-04", "has_results": true, "last_update_posted_date": "2023-10-30", "last_synced_at": "2026-09-26T02:21:09.321Z", "location_count": 4, "location_summary": "San Marcos, California • East Brunswick, New Jersey • Philadelphia, Pennsylvania + 1 more", "locations": [ { "city": "San Marcos", "state": "California" }, { "city": "East Brunswick", "state": "New Jersey" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03840200" }, { "nct_id": "NCT01485861", "title": "Study of Ipatasertib or Apitolisib With Abiraterone Acetate Versus Abiraterone Acetate in Participants With Castration-Resistant Prostate Cancer Previously Treated With Docetaxel Chemotherapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "Abiraterone", "type": "DRUG" }, { "name": "Apitolisib", "type": "DRUG" }, { "name": "Ipatasertib", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Prednisolone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 298, "start_date": "2012-01-11", "completion_date": "2022-08-31", "has_results": true, "last_update_posted_date": "2023-09-14", "last_synced_at": "2026-09-26T02:21:09.321Z", "location_count": 12, "location_summary": "Scottsdale, Arizona • San Francisco, California • Fort Myers, Florida + 9 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "San Francisco", "state": "California" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Honolulu", "state": "Hawaii" } ], "official_url": "https://clinicaltrials.gov/study/NCT01485861" } ] }